Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy

Hearing loss in Pompe disease revisited: results from a study of 24 children

(2010) Carine I. van Capelle et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience

(2010) Anupam Chakrapani et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: From our experience of 4 cases including an autopsy case

(2010) Hiroshi Kobayashi et al.   MOLECULAR GENETICS AND METABOLISM

Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease

(2009) Marc Nicolino et al.   GENETICS IN MEDICINE

Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease

(2009) Priya S Kishnani et al.   PEDIATRIC RESEARCH

Velopharyngeal insufficiency: current concepts in diagnosis and management

(2008) Emily F Rudnick et al.   Current Opinion in Otolaryngology & Head and Neck Surgery

Lysosomal Storage Diseases and the Blood-Brain Barrier

(2008) David Begley et al.   CURRENT PHARMACEUTICAL DESIGN

Pompe's disease

(2008) Ans T van der Ploeg et al.   LANCET

Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease

(2007) Maarten R. Drost et al.   MUSCLE & NERVE